Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Anca Prica, MD FRCP(C), Annette E Hay, Michael Crump, MD, Nicole Mittman, Lois E. Shepherd, Ralph Meyer, MDFRCPC, Kevin Imrie, MD, Nancy A. Risebrough, Marina S Djurfeldt, MSc, Bingshu E. Chen, Matthew Cheung, MD MS, FRCP

Blood (2017) 130 (Supplement 1): 4673.

https://doi.org/10.1182/blood.V130.Suppl_1.4673.4673

Published: 2017

Journal Articles

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Liam Smyth, MD FRCPath, Rena Buckstein, MD FRCPC, Pennell Nancy, BSc, Rashmi Weerasinghe, Matthew Cheung, MD MS, FRCP, Eugenia Piliotis, MD FRCP, MD, Kevin Imrie, MD, David Spaner, MD PhD, Marciano D. Reis, MD, Lisa Chodirker, MD, Zeina Ghorab, Violet ruth,nancy Milliken, Angela Boudreau, RN, BScN, MN, CON(C), Neil Berinstein, MD

Blood (2017) 130 (Supplement 1): 4069.

https://doi.org/10.1182/blood.V130.Suppl_1.4069.4069

Published: 2017

Journal Articles

The Use of Erythropoietic Agents in Patients with Non-Myeloid Hematological Malignancies.

Nadine Shehata, MD, MSc, Irwin Walker, MD, Ralph Meyer, MD, Adam Haynes, MSc, Kevin Imrie, MD

Blood (2006) 108 (11): 3338.

https://doi.org/10.1182/blood.V108.11.3338.3338

Published: 2006

Journal Articles

MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).

Robert E. Marcus, MB, Philippe Solal-Celigny, MD, Kevin Imrie, MD, FRCPC, John V. Catalano, MD, Anna Dmoszynska, MD, PHD, João C. Raposo, MD, Fritz C. Offner, MD, PHD, José Gomez-Codina, MD, PHD

Blood (2006) 108 (11): 481.

https://doi.org/10.1182/blood.V108.11.481.481

Published: 2006

Journal Articles

Mabthera (Rituximab) Plus CVP Chemotherapy for First-Line Treatment of Stage III/IV Follicular Non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-Up.

Philippe Solal-Celigny, MD, Kevin Imrie, MD, Andrew Belch, MD, Katherine Sue Robinson, MD, David Cunningham, Antonio Rueda, MD, John Catalano, MD, Fritz Offner, Jan Walewski, MD, João Raposo, MD, Paul Smith, MSc, Robert Marcus, MD

Blood (2005) 106 (11): 350.

https://doi.org/10.1182/blood.V106.11.350.350

Published: 2005

Journal Articles

A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma.

Nancy Pennell, M.Sc, Anthony Woods, MD, Rena Buckstein, MD, Kevin Imrie, MD, David Spaner, MD, Marciano Reis, MD, Neil Berinstein, MD

Blood (2004) 104 (11): 5203.

https://doi.org/10.1182/blood.V104.11.5203.5203

Published: 2004

Journal Articles

High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.

Anthony C. Woods, MD, Rena Buckstein, MD, Joy Mangel, MD, Kevin Imrie, MD, David Spaner, MD, Michael Crump, MD, Nancy Pennell, B.Sc, Angela Boudreau, M.Sc, Marciano Reis, MD, Neil Berinstein, MD

Blood (2004) 104 (11): 914.

https://doi.org/10.1182/blood.V104.11.914.914

Published: 2004

NARROW

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

The Use of Erythropoietic Agents in Patients with Non-Myeloid Hematological Malignancies.

MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).

Mabthera (Rituximab) Plus CVP Chemotherapy for First-Line Treatment of Stage III/IV Follicular Non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-Up.

A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma.

High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.

Email alerts

ASH Publications

American Society of Hematology

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

The Use of Erythropoietic Agents in Patients with Non-Myeloid Hematological Malignancies.

MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).

Mabthera (Rituximab) Plus CVP Chemotherapy for First-Line Treatment of Stage III/IV Follicular Non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-Up.

A Simplified Real-Time PCR Method for the Quantification of Minimal Residual Disease in Follicular Lymphoma.

High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only